India
· Delayed Price · Currency is INR Lupin Company Description
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally.
It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs).
The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities.
It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001.
Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
| Country | India |
| Founded | 1968 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 19,210 |
| CEO | Vinita Gupta |
Contact Details
Address: Kalpataru Inspire Mumbai, Maharashtra 400055 India | |
| Phone | 91 22 6640 2323 |
| Website | lupin.com |
Stock Details
| Ticker Symbol | LUPIN |
| Exchange | National Stock Exchange of India |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| ISIN Number | INE326A01037 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vinita D. Gupta | Chief Executive Officer and Executive Director |
| Ramesh Swaminathan | Executive Director, Global Chief Financial Officer, CRO and Head of API Plus SBU |
| Nilesh Deshbandhu Gupta | MD and Executive Director |
| Christoph Funke | Chief Technical Operations Officer |
| Sreeji Gopinathan | Chief Information Officer |
| Ravi Agrawal | Senior Vice President of Investor Relations and M&A |
| Dr. Sofia Mumtaz | President of Legal and Compliance of Australia, Japan and Canada Business |
| Amit Kumar Gupta | Company Secretary and Compliance Officer |
| Rajalakshmi Azariah | Vice President and Global Head of Corporate Communications |
| Dr. Fabrice Egros M.B.A., Ph.D., Pharm.D. | President of Global Corporate Development and Growth Markets |